Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Clinical Cancer Research
Clinical Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

CCR Translations

Small-Cell Neuroendocrine Tumors: Cell State Trumps the Oncogenic Driver

Matthew G. Oser and Pasi A. Jänne
Matthew G. Oser
1Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
2Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pasi A. Jänne
1Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
2Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
3Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Pasi_Janne@dfci.harvard.edu
DOI: 10.1158/1078-0432.CCR-17-3646 Published April 2018
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Small-cell neuroendocrine cancers often originate in the lung but can also arise in the bladder or prostate. Phenotypically, small-cell carcinoma of the bladder (SCCB) shares many similarities with small-cell lung cancer (SCLC). It is unknown whether SCCB and SCLC share common genetic driver mutations. Clin Cancer Res; 24(8); 1775–6. ©2018 AACR.

See related article by Chang et al., p. 1965

In this issue of Clinical Cancer Research, Chang and colleagues (1) perform DNA sequencing to characterize the mutational signature of small-cell carcinoma of the bladder (SCCB). They find that both SCCB and small-cell lung cancer (SCLC) harbor near universal loss-of-function mutations in RB1 and TP53. In contrast to the smoking mutational signature found in SCLC, SCCB has an APOBEC mutational signature, a signature also found in urothelial carcinoma. Furthermore, they show that SCCB and urothelial carcinoma share many common mutations that are distinct from mutations found in SCLC, suggesting that SCCB may arise from a preexisting urothelial cancer. To further explore this hypothesis, they sequenced distinct regions from mixed-histology tumor specimens that had both urothelial and small-cell components and found that the small-cell component uniquely harbored RB1 and TP53 mutations, providing stronger evidence that RB1 and TP53 loss is required for the development of SCCB and that SCCB arises from a preexisting urothelial cancer.

Urothelial cancers have a high frequency of mutations in chromatin-modifying enzymes, including mutations in KDM6A and ARID1A (2). SCCB, but not SCLC, shares these mutations in the same chromatin-modifying enzymes at similar frequencies to urothelial carcinoma, demonstrating that SCCB is unique from SCLC and raising the likely possibility that SCCB arises from a preexisting urothelial carcinoma. Although these are loss-of-function mutations and are not directly targetable, these genetic features of SCCB are not present in SCLC and are important to be cognizant of, as targeting chromatin-modifying enzymes is an active area of preclinical research and therapeutic opportunities may become available in the future.

Like SCLC, nearly all SCCBs harbor mutations in RB1 and TP53. In patients with mixed-histology tumors, RB1 and TP53 loss was present in the SCCB component, but not in the urothelial component, suggesting that RB1 and TP53 loss occurs after the initial development of the urothelial carcinoma and is required for transdifferentiation from urothelial cancer to SCCB. This is reminiscent of a similar phenomenon observed in two other tumors types: (i) EGFR-mutant lung cancer and (ii) castration-resistant prostate cancer, where RB1 and TP53 loss is necessary for the transdifferentiation from an adenocarcinoma to a small-cell neuroendocrine tumor. EGFR-mutant lung cancers acquire RB1 loss as a mechanism of resistance to EGFR tyrosine kinase inhibitors (3), and castration-resistant prostate cancers acquire RB1 and TP53 loss as a mechanism of resistance to androgen receptor (AR) blockade (4, 5). Both lung and prostate cancers that acquire RB1 and TP53 mutations are no longer responsive to inhibition of their respective oncogenic drivers (e.g., EGFR or AR) likely because gene expression of their respective oncogenic drivers is downregulated at the time of acquired resistance and transdifferentation to a small-cell neuroendocrine tumor (refs. 3–5; Fig. 1). In contrast to EGFR-mutant lung cancer or prostate cancer, urothelial cancers less frequently harbor recurrently mutated oncogenic drivers (2) and have no approved targeted therapies. There are, however, low-frequency mutations and amplifications in ERBB2 and ERBB3, which are also present in SCCB at similar frequencies and are potentially druggable targets. Chang and colleagues (1) also described a patient with a mixed-histology tumor and a hotspot mutation in PIK3CA Q546P that was found in both the urothelial and the small-cell component. It is not known whether there is protein expression of these candidate oncogenic drivers (ERBB2, ERBB3, or PI3K) in the SCCB tumors. Similar to lung and prostate cancers that have transdifferentiated to a small-cell neuroendocrine tumor (3–5), we hypothesize that as a consequence of inactivating RB1 and TP53 and becoming neuroendocrine, SCCB tumors downregulate expression of the activating oncogene (e.g., ERBB2) and as a result, become less addicted to these activating mutations (Fig. 1). Thus, it is likely that the loss of tumor suppressor genes RB1 and TP53, which are required for the small-cell neuroendocrine state, display the dominant phenotype. Once small-cell differentiation has occurred, the tumors are no longer addicted nor express these oncogenes that were initially required for their tumorigenesis (Fig. 1).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Pathogenesis of small-cell neuroendocrine tumors share a common pathway involving RB1 and TP53 loss. The pathogenesis of EGFR-mutant lung cancer (yellow), prostate cancer (blue), and bladder cancer (gray) all initially require and are dependent on a specific oncoprotein (EGFR for lung cancer, AR for prostate cancer, and sometimes ERBB2 for bladder cancer) for maintenance of tumorigenesis. Acquisition of the small-cell neuroendocrine state requires RB1 and TP53 loss, at which time EGFR and AR expression is downregulated. Although it is not known whether oncogenic drivers in bladder cancer are downregulated upon transdifferentiation to small-cell carcinoma, we hypothesize that this occurs as a consequence of the small-cell neuroendocrine state, but this hypothesis needs to be formally tested.

Chang and colleagues point out that roughly 10% of urothelial cancers harbor mutations in both RB1 and TP53, suggesting that RB1 and TP53 loss is not sufficient for the small-cell neuroendocrine state. This is consistent with EGFR-mutant lung cancer in that RB1 loss alone does not transdifferentiate EGFR-mutant adenocarcinoma to SCLC (3). However, in tumor xenograft models of prostate cancer, combined RB1 and TP53 loss induces robust increases in expression of the reprogramming transcription factor SOX2, which causes resistance to enzalutamide, downregulation of AR, and upregulation of neuroendocrine markers (chromogranin A and synaptophysin; ref. 5). Inactivation of SOX2 reverses these effects. It will be interesting to determine whether SOX2 deregulation upon RB1 and TP53 loss occurs selectively in prostate cancer, but not in EGFR-mutant lung cancer or bladder cancer, which may help explain why RB1 and TP53 loss is not sufficient to promote the transdifferentiation to a small-cell neuroendocrine phenotype in these tumor types. Future studies will also help elucidate what else is required in addition to RB1 and TP53 loss to drive the neuroendocrine phenotype in lung and bladder cancers.

The most common driver mutations in SCCB are loss-of-function mutations in RB1 and TP53. Developing new therapies in this setting has been challenging, as RB1 and TP53 are not directly targetable, and TP53 loss causes resistance to several therapies. However, there are new promising therapies that are being tested preclinically and in clinical trials (e.g., Rova-T, immuno-oncology) for SCLC. Do these new approaches that show efficacy in SCLC also show responses in SCCB given that each cancer has a distinct but overlapping pathogenesis? Likewise, will SCCB respond similarly to the several immuno-oncology agents that are now approved for metastatic urothelial carcinomas?

Disclosure of Potential Conflicts of Interest

P.A. Jänne reports receiving commercial research grants from Astellas Pharmaceuticals, AstraZeneca, Daiichi Sankyo, Eli Lilly and Company, and PUMA, holds ownership interest (including patents) in Lab Corp, and is a consultant/advisory board member for ACEA Biosciences, Araxes Pharmaceuticals, Ariad Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, Chugai Pharmaceuticals, Eli Lilly and Company, Ignyta, LOXO Oncology, Merrimack Pharmaceuticals, Pfizer, and Roche/Genentech. No potential conflicts of interest were disclosed by the other author.

Authors' Contributions

Conception and design: M.G. Oser

Writing, review, and/or revision of the manuscript: M.G. Oser, P.A. Jänne

Acknowledgments

M.G. Oser is supported by an NCI/NIH K08 grant (K08CA222657).

  • Received January 2, 2018.
  • Revision received January 16, 2018.
  • Accepted January 23, 2018.
  • Published first January 26, 2018.
  • ©2018 American Association for Cancer Research.

References

  1. 1.↵
    1. Chang MT,
    2. Penson A,
    3. Desai NB,
    4. Socci ND,
    5. Shen R,
    6. Seshan VE,
    7. et al.
    Small-cell carcinomas of the bladder and lung are characterized by a convergent but distinct pathogenesis. Clin Cancer Res 2018;24:1965–73.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Gui Y,
    2. Guo G,
    3. Huang Y,
    4. Hu X,
    5. Tang A,
    6. Gao S,
    7. et al.
    Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat Genet 2011;43:875–8.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Niederst MJ,
    2. Sequist LV,
    3. Poirier JT,
    4. Mermel CH,
    5. Lockerman EL,
    6. Garcia AR,
    7. et al.
    RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. Nat Commun 2015;6:6377.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Ku SY,
    2. Rosario S,
    3. Wang Y,
    4. Mu P,
    5. Seshadri M,
    6. Goodrich ZW,
    7. et al.
    Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science 2017;355:78–83.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Mu P,
    2. Zhang Z,
    3. Benelli M,
    4. Karthaus WR,
    5. Hoover E,
    6. Chen CC,
    7. et al.
    SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. Science 2017;355:84–8.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top
Clinical Cancer Research: 24 (8)
April 2018
Volume 24, Issue 8
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Clinical Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Small-Cell Neuroendocrine Tumors: Cell State Trumps the Oncogenic Driver
(Your Name) has forwarded a page to you from Clinical Cancer Research
(Your Name) thought you would be interested in this article in Clinical Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Small-Cell Neuroendocrine Tumors: Cell State Trumps the Oncogenic Driver
Matthew G. Oser and Pasi A. Jänne
Clin Cancer Res April 15 2018 (24) (8) 1775-1776; DOI: 10.1158/1078-0432.CCR-17-3646

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Small-Cell Neuroendocrine Tumors: Cell State Trumps the Oncogenic Driver
Matthew G. Oser and Pasi A. Jänne
Clin Cancer Res April 15 2018 (24) (8) 1775-1776; DOI: 10.1158/1078-0432.CCR-17-3646
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Disclosure of Potential Conflicts of Interest
    • Authors' Contributions
    • Acknowledgments
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Re-evaluating Eligibility Criteria in Cancer Clinical Trials
  • Clinical Utility of Lung Adenocarcinoma Subtypes
  • Combination Immunotherapy in HCC
Show more CCR Translations
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • CCR Focus Archive
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Clinical Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Clinical Cancer Research
eISSN: 1557-3265
ISSN: 1078-0432

Advertisement